Baird Medical Celebrates Listing on NASDAQ

October 2, 2024 — New York, NY — Baird Medical is pleased to announce its successful listing on the NASDAQ stock exchange. This achievement marks an important milestone in the company’s journey and positions Baird Medical for future growth in the global healthcare market. The listing further supports our mission to develop advanced microwave ablation (MWA) technology as a non-surgical alternative for treating various cancers, including thyroid nodules.

(Photography courtesy of Nasdaq, Inc.)

A Milestone Moment

Since its founding in 2012, Baird Medical has focused on developing innovative MWA technology aimed at providing minimally invasive treatment options. The company’s NASDAQ listing is expected to increase visibility and allow Baird Medical to expand its presence in the United States and other key international markets.

The bell-ringing ceremony, held at NASDAQ’s headquarters in New York, was attended by the company’s leadership team and key partners, reflecting Baird Medical’s dedication to creating impactful, patient-centric medical solutions.

(Photography courtesy of Nasdaq, Inc.)

Global Expansion and Regulatory Success

In China, Baird Medical became the first company to receive a Class III medical device registration certificate for its microwave ablation (MWA) systems. This regulatory approval, along with FDA clearance obtained in the U.S. in November 2023, underscores the company’s commitment to meeting stringent global standards and advancing the adoption of MWA technology in key international markets.

(Photography courtesy of Nasdaq, Inc.)

Moving Forward

With the support of our stakeholders, Baird Medical will continue to focus on expanding its technology offerings and clinical applications. As the company grows, maintaining compliance with all regulatory requirements and upholding the highest ethical standards remains a top priority.

(Photography courtesy of Nasdaq, Inc.)

Disclaimer:

This announcement may contain forward-looking statements, which are based on current assumptions and expectations. Actual results could differ materially from those expressed or implied due to various factors, including changes in market conditions, regulatory landscapes, and operational challenges. Readers are cautioned not to place undue reliance on these forward-looking statements, and the company undertakes no obligation to update them, except as required by law.

For more detailed information, please visit https://ir.bairdmed.com/.